Hutchison China MediTech Ltd ADR Stock
Hutchison China MediTech Ltd ADR dominated the market today, gaining €0.60 (3.450%).
Currently there is a rather positive sentiment for Hutchison China MediTech Ltd ADR with 5 Buy predictions and 0 Sell predictions.
Based on the current price of 18.3 € the target price of 45 € shows a potential of 145.9% for Hutchison China MediTech Ltd ADR which would more than double the current price.
Pros and Cons of Hutchison China MediTech Ltd ADR in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hutchison China MediTech Ltd ADR vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Hutchison China MediTech Ltd ADR | 3.450% | 5.780% | 17.308% | 15.823% | 15.823% | - | - |
China Resources Pharmaceutical Group Ltd | - | 0.000% | 0.847% | -30.814% | 2.586% | 8.182% | -54.371% |
China Traditional Chinese Medicine Co Ltd | 1.210% | 0.806% | 0.000% | 4.603% | 13.122% | 8.696% | 0.929% |
Opko Health Inc. | -1.990% | 3.324% | -2.352% | -8.830% | -14.933% | -64.295% | -42.276% |
Comments
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for HCM provided by MarketBeat
HUTCHMED (China) Limited (NASDAQ: HCM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for HCM provided by MarketBeat
HUTCHMED (China) Limited (NASDAQ: HCM) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "buy" rating. They now have a $22.10 price target on the stock.
Show more
Ratings data for HCM provided by MarketBeat